<DOC>
	<DOCNO>NCT02426372</DOCNO>
	<brief_summary>The purpose open-label , dose-ranging , exploratory study evaluate safety , tolerability , compliance , mechanism action efficacy QBECO site specific immunomodulation induction clinical response remission subject moderate severe ulcerative colitis</brief_summary>
	<brief_title>Safety Efficacy QBECO Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female subject reach age majority Willing learn able selfadminister study drug Diagnosis UC establish least 6 month screen visit , clinical endoscopic evidence . Currently experience moderate severe active UC define Mayo score 612 ( inclusive ) Screening . Endoscopic evidence active mucosal disease , assess flexible sigmoidoscopy , Endoscopic Finding Subscore ≥2 Screening . Rectal Bleeding Subscore ≥1 Screening . Physician 's Global Assessment Subscore ≥2 Screening . Male/female subject agree practice effective method contraception History colonic rectal surgery hemorrhoid surgery appendectomy Currently receive total parenteral nutrition Disease limit ulcerative proctitis Diagnosed Crohn 's disease , indeterminate colitis , microscopic colitis , ischemic infectious colitis Any known allergy hypersensitivity kill wholecell bacterial vaccine phenol Known human immunodeficiency virus ( HIV ) infection immunosuppressive disorder Concurrently participate another study receive experimental investigational therapy within past 3 month Females currently pregnant lactate Any history malignancy . Exceptions may apply cervical cancer form skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>